Higher serum levels of IGF-1 and lower levels of IGFBP-3 have been associated with increased risk of aggressive prostate cancer [42] although higher levels of IGFBP-3 have been observed in prostate tumor cells compared to benign cells, and are associated with higher cancer recurrence [43]. Here, IGF1 is linked to prostate carcinoma.